ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion...

Full description

Saved in:
Bibliographic Details
Main Authors BENARD, FRANCOIS, ROUSSEAU, JULIE MARIE, VAN DUIJNHOVEN, SANDER MARTINUS JOHANNES, NELSON, BRAD, TWUMASI-BOATENG, KWAME, SMAZYNSKI, JULIAN, BERGQVIST, JAN PETER, CUMMINS, EMMA J, KWOK, YIN YU EUNICE, LIN, KUO-SHYAN
Format Patent
LanguageEnglish
French
Published 22.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells. L'invention concerne des anticorps qui se lient de manière spécifique à l'antigène B5 du virus de la vaccine (VV B5). Dans certains modes de réalisation, les anticorps anti-VV B5 sont des anticorps humanisés. L'invention concerne également des protéines de fusion et des conjugués comprenant de tels anticorps. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps, des protéines de fusion et des conjugués selon la présente invention, ainsi que des procédés d'utilisation de telles compositions, par exemple, pour une thérapie, une imagerie in vivo et/ou similaire. Selon certains aspects, l'invention concerne des méthodes comprenant l'administration d'un anticorps, une protéine de fusion ou un conjugué selon la présente invention à un individu, l'individu présentant des cellules infectées par un VV, et l'anticorps, la protéine de fusion ou le conjugué étant dirigés contre les cellules infectées par des antigènes du VV B5 exprimés sur la surface des cellules infectées.
AbstractList Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells. L'invention concerne des anticorps qui se lient de manière spécifique à l'antigène B5 du virus de la vaccine (VV B5). Dans certains modes de réalisation, les anticorps anti-VV B5 sont des anticorps humanisés. L'invention concerne également des protéines de fusion et des conjugués comprenant de tels anticorps. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps, des protéines de fusion et des conjugués selon la présente invention, ainsi que des procédés d'utilisation de telles compositions, par exemple, pour une thérapie, une imagerie in vivo et/ou similaire. Selon certains aspects, l'invention concerne des méthodes comprenant l'administration d'un anticorps, une protéine de fusion ou un conjugué selon la présente invention à un individu, l'individu présentant des cellules infectées par un VV, et l'anticorps, la protéine de fusion ou le conjugué étant dirigés contre les cellules infectées par des antigènes du VV B5 exprimés sur la surface des cellules infectées.
Author SMAZYNSKI, JULIAN
VAN DUIJNHOVEN, SANDER MARTINUS JOHANNES
BERGQVIST, JAN PETER
NELSON, BRAD
LIN, KUO-SHYAN
BENARD, FRANCOIS
CUMMINS, EMMA J
TWUMASI-BOATENG, KWAME
KWOK, YIN YU EUNICE
ROUSSEAU, JULIE MARIE
Author_xml – fullname: BENARD, FRANCOIS
– fullname: ROUSSEAU, JULIE MARIE
– fullname: VAN DUIJNHOVEN, SANDER MARTINUS JOHANNES
– fullname: NELSON, BRAD
– fullname: TWUMASI-BOATENG, KWAME
– fullname: SMAZYNSKI, JULIAN
– fullname: BERGQVIST, JAN PETER
– fullname: CUMMINS, EMMA J
– fullname: KWOK, YIN YU EUNICE
– fullname: LIN, KUO-SHYAN
BookMark eNrjYmDJy89L5WTwdvQL8dQNc3R29vTzdFQI8wwKDVYAibm7-oFpJ38XT1eQkItCkKuPY4iri4Kzv2-Af7BniKe_H0TC1zXEw98lmIeBNS0xpziVF0pzMyi4uYY4e-imFuTHpxYXJCan5qWWxDs7GhsZGloamzoaGhOhBABSei7g
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate ANTICORPS ANTI-ANTIGENE DU VIRUS DE LA VACCINE ET COMPOSITIONS ET PROCEDES ASSOCIES
ExternalDocumentID CA3211935A1
GroupedDBID EVB
ID FETCH-epo_espacenet_CA3211935A13
IEDL.DBID EVB
IngestDate Fri Sep 27 05:30:54 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CA3211935A13
Notes Application Number: CA20223211935
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220922&DB=EPODOC&CC=CA&NR=3211935A1
ParticipantIDs epo_espacenet_CA3211935A1
PublicationCentury 2000
PublicationDate 20220922
PublicationDateYYYYMMDD 2022-09-22
PublicationDate_xml – month: 09
  year: 2022
  text: 20220922
  day: 22
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies ADMARE THERAPEUTICS SOCIETY
UVIC INDUSTRY PARTNERSHIPS INC
PROVINCIAL HEALTH SERVICES AUTHORITY
RelatedCompanies_xml – name: UVIC INDUSTRY PARTNERSHIPS INC
– name: PROVINCIAL HEALTH SERVICES AUTHORITY
– name: ADMARE THERAPEUTICS SOCIETY
Score 3.4183125
Snippet Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220922&DB=EPODOC&locale=&CC=CA&NR=3211935A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-L8Ig_St-JouoY9FOnSzlXpB2tX9jaWLoW9dMNV_Pe9hG36ok8JOQjh4O5-l-R-B_BEVZ8jKhdmhWjEtGVvaQpaUnMhqcOETTEka7bP2BlP7bdZf9aC1b4WRvOEfmlyRLSoEu290f5683OJ5eu_ldtnscKl9csod31jlx1bVm9gWYY_dIM08RNucO5yz4gnLlVMZrTvYaJ0hCiaKWMIiqEqStn8jiijczhOcbO6uYCWrDtwyveN1zpwEu3eu3G6M73tJbx7cR6ahcd5GIceKcLJNCNq7TWI9ThMFLTDqU9UHwz0SIQnUZpkoa4U1oIoyMeJn10BGQU5H5t4qvlBA3PuHc5Pr6Fdr2t5A2TgVEshRMlK5tgLibksEwPJKkQk0kHk14Xun9vc_iO7gzOlSvUrwrLuod18fMoHDL2NeNRK-waMpYFC
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da8IwED_Ejbm3zW3MffZh9K1MmtrShzJqWtdO-4HW4puYGsGXKtqxf3-XUN1etqeEHIRwcHe_S3K_A3ghos8R4QtthWhEM3h3qTFSEG3BiWkxg2BIlmyfsRlMjY9Zb9aA9aEWRvKEfklyRLSoAu29kv56-3OJ5cm_lftXtsalzdsgczy1zo51vWvruur1HT9NvISqlDrUVeOxQwSTGem5mCidIMK2hDH4eV8UpWx_R5TBBZymuFlZXUKDl21o0UPjtTacRfV7N05r09tfwdCNs1DLXUrDOHSVPBxPJ4pYe_djOfYTAe1w6imiDwZ6JIUmUZpMQlkpLAWRnwWJN7kGZeBnNNDwVPOjBubUPZ6f3ECz3JT8FhTbXC0ZY4VVWKax4JjLWszm1goRCTcR-XWg8-c2d__InqEVZNFoPgrj4T2cC7WKHxK6_gDNavfJHzEMV-xJKvAbyF6ENQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTI-VACCINIA+VIRUS+ANTIGEN+ANTIBODIES+AND+RELATED+COMPOSITIONS+AND+METHODS&rft.inventor=BENARD%2C+FRANCOIS&rft.inventor=ROUSSEAU%2C+JULIE+MARIE&rft.inventor=VAN+DUIJNHOVEN%2C+SANDER+MARTINUS+JOHANNES&rft.inventor=NELSON%2C+BRAD&rft.inventor=TWUMASI-BOATENG%2C+KWAME&rft.inventor=SMAZYNSKI%2C+JULIAN&rft.inventor=BERGQVIST%2C+JAN+PETER&rft.inventor=CUMMINS%2C+EMMA+J&rft.inventor=KWOK%2C+YIN+YU+EUNICE&rft.inventor=LIN%2C+KUO-SHYAN&rft.date=2022-09-22&rft.externalDBID=A1&rft.externalDocID=CA3211935A1